Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05192382
PHASE3

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

Sponsor: Crinetics Pharmaceuticals Inc.

View on ClinicalTrials.gov

Summary

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

Official title: A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

111

Start Date

2021-12-17

Completion Date

2028-01

Last Updated

2026-04-01

Healthy Volunteers

No

Conditions

Interventions

DRUG

Paltusotine

Paltusotine, tablets, once daily by mouth

DRUG

Placebo

Placebo, tablets, once daily by mouth

Locations (57)

Crinetics Study Site

Aurora, Colorado, United States

Crinetics Study Site

Boston, Massachusetts, United States

Crinetics Study Site

Columbus, Ohio, United States

Crinetics Study Site

Portland, Oregon, United States

Crinetics Study Site

Philadelphia, Pennsylvania, United States

Crinetics Study Site

Pittsburgh, Pennsylvania, United States

Crinetics Study Site

CABA, Buenos Aires, Argentina

Crinetics Study Site

Buenos Aires, Argentina

Crinetics Study Site

CABA, Argentina

Crinetics Study Site

CABA, Argentina

Crinetics Study Site

Córdoba, Argentina

Crinetics Study Site

Fortaleza, Ceará, Brazil

Crinetics Study Site

Belo Horizonte, Minas Gerais, Brazil

Crinetics Study Site

Curitiba, Paraná, Brazil

Crinetics Study Site

Botucatu, São Paulo, Brazil

Crinetics Study Site

Campinas, São Paulo, Brazil

Crinetics Study Site

Rio de Janeiro, Brazil

Crinetics Study Site

São Paulo, Brazil

Crinetics Study Site

São Paulo, Brazil

Crinetics Study Site

Sofia, Bulgaria

Crinetics Study Site (b)

Beijing, Beijing Municipality, China

Crinetics Study Site

Guangzhou, Guangdong, China

Crinetics Study Site

Shijiazhuang, Hebei, China

Crinetics Study Site

Zhengzhou, Henan, China

Crinetics Study Site

Wuhan, Hubei, China

Crinetics Study Site

Changsha, Hunan, China

Crinetics Study Site

Jinan, Shandong, China

Crinetics Study Site

Xi’an, Shanxi, China

Crinetics Study Site

Chengdu, Sichuan, China

Crinetics Study Site

Hangzhou, Zhejiang, China

Crinetics Study Site

Marseille, France

Crinetics Study Site

Pessac, France

Crinetics Study Site

Toulouse, France

Crinetics Study Site

Aachen, Germany

Crinetics Study Site

Berlin, Germany

Crinetics Study Site

München, Germany

Crinetics Study Site

München, Germany

Crinetics Study Site

Würzburg, Germany

Crinetics Study Site

Athens, Greece

Crinetics Study Site (b)

Athens, Greece

Crinetics Study Site

Thessaloniki, Greece

Crinetics Study Site

Budapest, Hungary

Crinetics Study Site

Budapest, Hungary

Crinetics Study Site

Pécs, Hungary

Crinetics Study Site

Bangalore, Karnataka, India

Crinetics Study Site

Belagavi, Karnataka, India

Crinetics Study Site

Kochi, Kerala, India

Crinetics Study Site

Mumbai, Maharashtra, India

Crinetics Study Site

Chandigarh, India

Crinetics Study Site

Delhi, India

Crinetics Study Site

Petah Tikva, Israel

Crinetics Study Site

Roma, Italy

Crinetics Study Site

Bydgoszcz, Poland

Crinetics Study Site

Poznan, Poland

Crinetics Study Site

Wroclaw, Poland

Crinetics Study Site

Barcelona, Spain

Crinetics Study Site

London, United Kingdom